ArticleMolecular oncology2010
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.
Article in Molecular oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review.Molecular cancer · 2019Pooled it
- Circulating Tumor Microenvironment in Metastasis.Cancer research · 2025Review
- Malignant pleural disease.Breathe (Sheffield, England) · 2023Review
- Impact of Selected Serum Factors on Metastatic Potential of Gastric Cancer Cells.Diagnostics (Basel, Switzerland) · 2022Article
- Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5Cell death & disease · 2020Article
- Technical Considerations in Ex Vivo Human Regulatory T Cell Migration and Suppression Assays.Cells · 2020Review
- Cellular communication promotes mammosphere growth and collective invasion through microtubule‑like structures and angiogenesis.Oncology reports · 2018Article
- The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review).Molecular medicine reports · 2018Review
- Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition.Drug design, development and therapy · 2017Article
- Cancer cells remodel themselves and vasculature to overcome the endothelial barrier.Cancer letters · 2016Review
- Inhibition of lung tumor growth in nude mice by siRNAOncology letters · 2014Article
- Hypoxia and HIFs in regulating the development of the hematopoietic system.Blood cells, molecules & diseases · 2013Review
- The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.Current oncology reports · 2013Review
- Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.Journal of translational medicine · 2013Article
- Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.Molecular cancer · 2013Article
- Pre-conditioned mesenchymal stem cells ameliorate renal ischemic injury in rats by augmented survival and engraftment.Journal of translational medicine · 2012Article
- Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.Experimental cell research · 2012Article
- Oxygen tension plays a critical role in the hematopoietic microenvironment in vitro.Haematologica · 2012Article
- Selection of peptide inhibitor to matrix metalloproteinase-2 using phage display and its effects on pancreatic cancer cell lines PANC-1 and CFPAC-1.International journal of biological sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Cancer progression is often associated with the formation of malignant effusions. Vascular endothelial growth factor (VEGF) is a major regulator of vascular permeability and has been implicated as mediator of tumor progression. We examined the production and secretion of VEGF(165) in various primary cancer cells derived from malignant effusions, and the role of exogenous VEGF(165) as a mediator of effusion formation. VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin. Secreted VEGF(165) showed functional activity by inducing endothelial leakiness and tumor cell-transendothelial migration in vitro, effects which could be reverted by the anti-VEGF antibody bevacizumab. Thus, mTOR inhibitors as well as bevacizumab should be considered as potential agents in cancer patients suffering from malignant effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.